Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published.

Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract for a poster presentation at the ESMO Congress 2023 today has been published online on the ESMO website.

After the submission of the abstract, the data set to be included in the poster presentation on Monday 23 October was expanded. The majority of the patients are still early in the treatment course, and responses will continue to evolve.

Details for the poster session are as follows:

Abstract Title: Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: interim results from the ATLAS-IT-05 trial

Poster Number:  1051P

Session: Investigational immunotherapy

Session Date and Time: Monday, October 23, 2023

Session Location: Hall 8

Dr. Øystein Rekdal, Chief Executive Officer at Lytix Biopharma, commented: “The ATLAS-IT-05 study presents an opportunity to demonstrate whether LTX-315 in combination with pembrolizumab treatment could enhance the clinical outcome in PD-1 / PD-L1 refractory melanoma patients. We are looking forward to presenting interim data at ESMO even though this is very early in the study as the treatment cycles have not been completed for the majority of the patients included.”